NCT01020994

Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema

Explorative, Double-blind, Randomized, Controlled Multi-center Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41003 Once Daily Versus LAS189962 and LAS189961 in the Treatment of Superficial Infected Eczema

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Almirall, S.A. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to determine the efficacy and safety of topical application of LAS41003 in comparison to LAS189962 and LAS189961 in the treatment of superinfected eczema.

Conditions

• Eczema

Interventions

Type	Name	Description
DRUG	LAS41003	Once daily, topically
DRUG	LAS189962	Once daily, topically
DRUG	LAS189961	Once daily, topically

Timeline

• Start date: 2009-11-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2009-11-26
• Last updated: 2010-07-09

Locations

1 site across 1 country: Germany